1. Azuma, J., Aoki, T., Yamamoto, I., Seto, Y., Tokuda, K., Horiuchi, M., Sato, H., Mano, A., Ogawa, K. and Ootani, Y. (1998): A Phase I Study of a New Antiviral Drug, Valaciclovir Hydrochloride(256U87), in Healthy Male Volunteers. Rinsho Iyaku, 14, 2683-2700.
2. Helldén, A., Odar-Cederlöf, I., Diener, P., Barkholt, L., Medin, C., Svensson, J., Säwe, J. and Ståhle, L. (2003): High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol. Dial. Transplant., 18, 1135-1141.
3. Helldén, A., Lycke, J., Vander, T., Svensson, J., Odar-Cederlöf, I. and Ståhle, L. (2006): The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J. Antimicrob. Chemother., 57, 945-949.
4. Iijima, M., Hasegawa, T., Shibata, S., Miyakawa, H. and Uchigata, M. (2003): Neurotoxicity of valacyclovir in a patient on hemodialysis. Neurol. Med., 58, 327-329.
5. Kokubo, T., Hirata, J., Oota, M., Fujita, M. and Yamakawa, T. (2004): Relationship between acyclovir pharmacokinetics and neuropsychiatric adverse effects in dialysis patients. [Translated from Japanese.] Tousekikanjya ni okeru acyclovir tainaidoutai to seishinshinkeikei no yuugaisayouhatugen no kanrensei. Journal of Osaka Society for Dialysis Therapy., 22, 153-157. (in Japanese.)